Ultrasound-induced blood-brain barrier disruption for the treatment of gliomas and other primary CNS tumors
- PMID: 32112904
- DOI: 10.1016/j.canlet.2020.02.013
Ultrasound-induced blood-brain barrier disruption for the treatment of gliomas and other primary CNS tumors
Abstract
The treatment of primary brain tumors, especially malignant gliomas, remains challenging. The failure of most treatments for this disease is partially explained by the blood-brain barrier (BBB), which prevents circulating molecules from entering the brain parenchyma. Ultrasound-induced BBB disruption (US-BBBD) has recently emerged as a promising strategy to improve the delivery of therapeutic agents to brain tumors. A large body of preclinical studies has demonstrated that the association of low-intensity pulsed ultrasound with intravenous microbubbles can transiently open the BBB in a localized manner. The safety of this technique has been assessed in numerous preclinical studies in both small and large animal models. A large panel of therapeutic agents have been delivered to the brain in preclinical models, demonstrating both tumor control and increased survival. This technique has recently entered clinical trials with encouraging preliminary data. In this review, we describe the mechanisms and histological effects of US-BBBD and summarize the preclinical studies published to date. We furthermore provide an overview of the current clinical development and future potential of this promising technology.
Keywords: Blood-brain barrier; Brain tumors; Glioblastoma; Low-intensity pulsed ultrasound; Ultrasound.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest M. Canney and Guillaume Bouchoux are employees of CarThera. A. Carpentier is a paid consultant to CarThera. K. Beccaria has previously been employed by CarThera. A. Carpentier, K. Beccaria, and M. Canney, and G. Bouchoux are inventors on intellectual property related to the SonoCloud® device that has been licensed to CarThera. A. Carpentier and M. Canney have ownership interest in CarThera.
Similar articles
-
Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives.Neurosurg Focus. 2020 Jan 1;48(1):E10. doi: 10.3171/2019.10.FOCUS19726. Neurosurg Focus. 2020. PMID: 31896084 Review.
-
Focused ultrasound therapy as a strategy for improving glioma treatment.J Neurosurg. 2025 Jan 24;142(6):1635-1644. doi: 10.3171/2024.9.JNS24721. Print 2025 Jun 1. J Neurosurg. 2025. PMID: 39854698 Review.
-
Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models.Clin Cancer Res. 2021 Aug 1;27(15):4325-4337. doi: 10.1158/1078-0432.CCR-20-3760. Epub 2021 May 24. Clin Cancer Res. 2021. PMID: 34031054 Free PMC article.
-
Blood-brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors.J Neurooncol. 2021 Jan;151(1):65-73. doi: 10.1007/s11060-020-03425-8. Epub 2020 Feb 28. J Neurooncol. 2021. PMID: 32112296 Review.
-
Closed-loop control of targeted ultrasound drug delivery across the blood-brain/tumor barriers in a rat glioma model.Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):E10281-E10290. doi: 10.1073/pnas.1713328114. Epub 2017 Nov 13. Proc Natl Acad Sci U S A. 2017. PMID: 29133392 Free PMC article.
Cited by
-
Targeting cannabidiol to specific areas of the brain: an ultrasound-based strategy.Neural Regen Res. 2020 Dec;15(12):2247-2248. doi: 10.4103/1673-5374.284992. Neural Regen Res. 2020. PMID: 32594040 Free PMC article. No abstract available.
-
Mapping Knowledge Structure and Research Frontiers of Ultrasound-Induced Blood-Brain Barrier Opening: A Scientometric Study.Front Neurosci. 2021 Jul 14;15:706105. doi: 10.3389/fnins.2021.706105. eCollection 2021. Front Neurosci. 2021. PMID: 34335175 Free PMC article.
-
An Affordable and Easy-to-Use Focused Ultrasound Device for Noninvasive and High Precision Drug Delivery to the Mouse Brain.IEEE Trans Biomed Eng. 2022 Sep;69(9):2723-2732. doi: 10.1109/TBME.2022.3150781. Epub 2022 Aug 19. IEEE Trans Biomed Eng. 2022. PMID: 35157574 Free PMC article.
-
Glioblastoma chemoresistance: roles of the mitochondrial melatonergic pathway.Cancer Drug Resist. 2020 Jun 16;3(3):334-355. doi: 10.20517/cdr.2020.17. eCollection 2020. Cancer Drug Resist. 2020. PMID: 35582450 Free PMC article. Review.
-
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.Front Immunol. 2021 Oct 5;12:721830. doi: 10.3389/fimmu.2021.721830. eCollection 2021. Front Immunol. 2021. PMID: 34675919 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
